Search results
Results from the WOW.Com Content Network
Two other isomers are also known: 2-trifluoromethylbenzaldehyde and 3-trifluoromethylbenzaldehyde. These compounds are derivatives of benzaldehyde with trifluoromethyl substituents. The CF 3 group enhances the electrophilicity of the formyl group and provides a label for analysis by fluorine-19 nuclear magnetic resonance spectroscopy.
The first to investigate trifluoromethyl groups in relationship to biological activity was F. Lehmann in 1927. [5] An early review appeared in 1958. [6] An early synthetic method was developed by Frédéric Swarts in 1892, [7] based on antimony fluoride.
Tetrakis[3,5-bis(trifluoromethyl)phenyl]borate is an anion with chemical formula [{3,5-(CF 3) 2 C 6 H 3} 4 B] −, which is commonly abbreviated as [BAr F 4] −, indicating the presence of fluorinated aryl (Ar F) groups. It is sometimes referred to as Kobayashi's anion in honour of Hiroshi Kobayashi who led the team that first synthesised it. [1]
The trifluoromethyl group is a functional group that has the formula-CF 3. The naming of is group is derived from the methyl group (which has the formula -CH 3), by replacing each hydrogen atom by a fluorine atom. Some common examples are trifluoromethane H– CF 3, 1,1,1-trifluoroethane H 3 C – CF 3, and hexafluoroacetone F 3 C –CO– CF 3.
The Julia-Kocienski olefination serves as a powerful reaction in the synthesis of resveratrol analogues with 3,5-bis(trifluoromethyl)phenyl sulfones. The following schematic displays the general scheme for synthesizing resveratrol analogues, where R 2 is an aryl group.
Brookhart's acid is the salt of the diethyl ether oxonium ion and tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BAr′ 4). It is a colorless solid, used as a strong acid. The compound was first reported by Volpe, Grant, and Brookhart in 1992. [1]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Burapitant (SSR-240,600) is a drug developed by Sanofi-Aventis which was one of the first compounds developed that acts as a potent and selective antagonist for the NK 1 receptor.